. 
You can learn more about SPARK at Stanford here, and if you’d like to connect with a member of our team, please fill out the form below.
We’re also excited to share that our CEO, Barry Bunin, PhD, will be presenting insights from his new book, Inside CDD Vault—a look at the people, values, and personal journeys behind the software helping scientists discover new medicines. The book explores how CDD grew as a for-profit, for-purpose company shaped by collaboration, resilience, and a mission to support scientific progress for the greater good.
You can also view book testimonials here.
Location: LKSC120 at the Stanford Med Center
Time: 5:30 PM – 7:30 PM
Barry Bunin, Ph.D.
CEO and Board Director
Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $100 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.
Dr. Bunin was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored “Chemoinformatics: Theory, Practice, and Products” (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and “The Combinatorial Index” (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.